These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12760877)

  • 1. Chlamydia pneumoniae resists antibiotics in lymphocytes.
    Yamaguchi H; Friedman H; Yamamoto M; Yasuda K; Yamamoto Y
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1972-5. PubMed ID: 12760877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
    Kutlin A; Roblin PM; Hammerschlag MR
    J Antimicrob Chemother; 2002 May; 49(5):763-7. PubMed ID: 12003969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
    Riska PF; Kutlin A; Ajiboye P; Cua A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
    Roblin PM; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
    Donati M; Rodrìguez Fermepin M; Olmo A; D'Apote L; Cevenini R
    J Antimicrob Chemother; 1999 Jun; 43(6):825-7. PubMed ID: 10404322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
    Kuo CC; Jackson LA; Lee A; Grayston JT
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2669-70. PubMed ID: 8913488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.
    Hammerschlag MR
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():35-9. PubMed ID: 10824030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
    Welsh L; Gaydos C; Quinn TC
    Antimicrob Agents Chemother; 1996 Jan; 40(1):212-4. PubMed ID: 8787907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts.
    Haranaga S; Ikejima H; Yamaguchi H; Friedman H; Yamamoto Y
    Clin Diagn Lab Immunol; 2002 Mar; 9(2):313-9. PubMed ID: 11874869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
    Hammerschlag MR; Roblin PM
    J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.
    Kutlin A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2002 Feb; 46(2):409-12. PubMed ID: 11796350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae.
    Gnarpe J; Eriksson K; Gnarpe H
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1843-5. PubMed ID: 8843291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.
    Gieffers J; Füllgraf H; Jahn J; Klinger M; Dalhoff K; Katus HA; Solbach W; Maass M
    Circulation; 2001 Jan; 103(3):351-6. PubMed ID: 11157684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
    Hammerschlag MR; Roblin PM
    Int J Antimicrob Agents; 2000 Jul; 15(2):149-52. PubMed ID: 10854812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells.
    Morinaga Y; Yanagihara K; Miyashita N; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Mukae H; Yamada Y; Kohno S; Kamihira S
    Pulm Pharmacol Ther; 2009 Dec; 22(6):580-6. PubMed ID: 19716898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
    Roblin PM; Hammerschlag MR
    Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
    Hammerschlag MR; Qumei KK; Roblin PM
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.
    Niki Y; Kimura M; Miyashita N; Soejima R
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2296-9. PubMed ID: 7840560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.